Disease · MONDO_0800385
iron poisoning
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. iron poisoning. Diseases, record MONDO_0800385. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0800385
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- iron poisoning
- Open Targets ID
- MONDO_0800385
- Other names
- iron overload, iron toxicity
- Highest stage of its drugs
- Approval, for 2 of its 12 drugs, from ClinicalTrials.gov and EMA Human Drugs
Source Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DEFERASIROX | CHEMBL550348 | Small molecule | Approval | EMA Human Drugs | 20 | 17 | 17 | Drugs and targets |
| DEFERIPRONE | CHEMBL70927 | Small molecule | Approval | ClinicalTrials.gov and EMA Human Drugs | 8 | 6 | 6 | Drugs and targets |
| DEFEROXAMINE | CHEMBL556 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| AMLODIPINE | CHEMBL1491 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| HONEY | CHEMBL2108391 | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| HYDROXYUREA | CHEMBL467 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OMEGA-3 FATTY ACIDS | CHEMBL4298065 | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| DEFERITAZOLE | CHEMBL487465 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DEFERITAZOLE MAGNESIUM | CHEMBL4297209 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PYRIDOXAL ISONICOTINOYL HYDRAZONE | CHEMBL103111 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets7
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CACNA1C | Voltage-gated L-type calcium channel | 2 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 2 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 2 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 2 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/779 | Drugs and targets |
| RRM1 | Ribonucleoside-diphosphate reductase RR1 | 1 | Ribonucleoside-diphosphate reductase RR1 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6240 | Drugs and targets |
| RRM2 | Ribonucleoside-diphosphate reductase RR1 | 1 | Ribonucleoside-diphosphate reductase RR1 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6241 | Drugs and targets |
| RRM2B | Ribonucleoside-diphosphate reductase RR1 | 1 | Ribonucleoside-diphosphate reductase RR1 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/50484 | Drugs and targets |
Trials31
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00235391 | Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload | Phase 3 | 1,683 | 2011-05-02 | Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis | DEFERASIROX | Its record names the disease | ClinicalTrials.gov |
| NCT02435212 | Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload | Phase 2 | 224 | 2024-09-19 | Transfusion-dependent Anemia | DEFERASIROX | Its record names the disease | ClinicalTrials.gov |
| NCT00600938 | Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload | Phase 2 | 197 | 2014-08-27 | Transfusional Iron Overload, Transfusional Hemosiderosis | DEFERASIROX, DEFEROXAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT00873041 | Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study | Phase 2 | 166 | 2012-09-25 | Non-transfusion Dependent Thalassemia | DEFERASIROX | Its record names the disease | ClinicalTrials.gov |
| NCT02443545 | Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias | Phase 4 | 134 | 2024-01-10 | Iron Overload, Sickle Cell Disease, Other Anemias | DEFERIPRONE | Its record names the disease | ClinicalTrials.gov |
| NCT00529152 | Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients | Phase 3 | 100 | 2009-08-12 | Iron Overload | DEFERIPRONE | Its record names the disease | ClinicalTrials.gov |
| NCT01254227 | Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload | Phase 2 | 60 | 2021-06-24 | Cardiac Iron Overload | DEFERASIROX, DEFEROXAMINE | Its record names the disease | ClinicalTrials.gov |
| NCT01186419 | Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload | Phase 2 | 51 | 2015-06-03 | Transfusional Iron Overload, Beta-thalassemia | DEFERITAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT00395629 | Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis | Phase 1/2 | 49 | 2011-05-18 | Iron Overload, Hereditary Hemochromatosis | DEFERASIROX | Its record names the disease | ClinicalTrials.gov |
| NCT01604941 | Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy | Phase 2 | 32 | 2015-08-17 | Iron Overload Due to Repeated Red Blood Cell Transfusions | DEFERITAZOLE MAGNESIUM | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 31
See all 31 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Core: Deferasirox (ICL). For Extension Labeled as ICL to ICL vs Core; Deferoxamine (DFO). For Extension Labeled as DFO to DFO: Core Study: Cardiac Function and the Proportion of Patients Dropping Out Due to Cardiac Dysfunction After Treatment With Deferasirox vs. Deferoxamine | 3 of 98 | 2 of 99 | 197 | NCT00600938 | Trial comparisons |
| SPD602 16 mg/kg/d vs SPD602 32 mg/kg/d: serious adverse events | 3 of 24 | 2 of 27 | 51 | NCT01186419 | Trial comparisons |
| SPD602 50mg/kg/Day vs SPD602 75mg/kg/Day: serious adverse events | 2 of 12 | 2 of 7 | 19 | NCT01604941 | Trial comparisons |
| Arm I vs Correlative: Cumulative Incidence of Documented Bacterial, Fungal, and Viral Infections | 2 of 4 | 5 of 5 | 9 | NCT01273766 | Trial comparisons |
Papers from its trials19
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0800385
GET https://conductscience.org/api/diseases/v1/MONDO_0800385/trials?page=2